John L Marshall

List of Publications by Year
in descending order

160 papers	5,380 citations	117625 34 h-index	95266 68 g-index
162 all docs	162 docs citations	162 times ranked	8159 citing authors

#	Article	IF	Citations
1	Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic Implications. Journal of the National Cancer Institute, 2022, 114, 271-279.	6.3	27
2	Association of Homologous Recombinationâ€“DNA Damage Response Gene Mutations with Immune Biomarkers in Gastroesophageal Cancers. Molecular Cancer Therapeutics, 2022, 21, 227-236.	4.1	4
3	The Essentials of Multiomics. Oncologist, 2022, 27, 272-284.	3.7	11
4	A Randomized Phase II Trial of mFOLFOX6 + Bevacizumab Alone or with AdCEA Vaccine + Avelumab Immunotherapy for Untreated Metastatic Colorectal Cancer. Oncologist, 2022, 27, 198-209.	3.7	18
5	Identification and characterization of recurrent neoantigens in upper gastrointestinal (GI) cancers.. Journal of Clinical Oncology, 2022, 40, 246-246.	1.6	0
6	Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic Adenocarcinoma. Clinical Cancer Research, 2022, 28, 2704-2714.	7.0	57
7	Comprehensive Analysis of R-Spondin Fusions and RNF43 Mutations Implicate Novel Therapeutic Options in Colorectal Cancer. Clinical Cancer Research, 2022, 28, 1863-1870.	7.0	16
8	Molecular profiling of signet-ring-cell carcinoma (SRCC) from the stomach and colon reveals potential new therapeutic targets. Oncogene, 2022, 41, 3455-3460.	5.9	19
9	The current state of molecular profiling in gastrointestinal malignancies. Biology Direct, 2022, 17, .	4.6	5
10	Abstract 1231: Prognostic and predictive drug-induced gene signatures for colorectal cancer patients personalized based on p53 status and treatment with FOLFOX, 5-FU, oxaliplatin, or irinotecan. Cancer Research, 2022, 82, 1231-1231.	0.9	0
11	Clinical Validation of a Machine-learningâ€“derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer. Clinical Cancer Research, 2021, 27, 1174-1183.	7.0	28
12	SPTBN1 inhibits inflammatory responses and hepatocarcinogenesis via the stabilization of SOCS1 and downregulation of p65 in hepatocellular carcinoma. Theranostics, 2021, 11, 4232-4250.	10.0	26
13	A phase I trial of the mTOR inhibitor temsirolimus in combination with capecitabine in patients with advanced malignancies. Cancer Medicine, 2021, 10, 1944-1954.	2.8	12
14	Pan-cancer analysis of RNA expression of ANGIOTENSIN-I-CONVERTING ENZYME 2 reveals high variability and possible impact on COVID-19 clinical outcomes. Scientific Reports, 2021, 11, 5639.	3.3	1
15	Machine learning analysis using 77,044 genomic and transcriptomic profiles to accurately predict tumor type. Translational Oncology, 2021, 14, 101016.	3.7	22
16	The Landscape of Alterations in DNA Damage Response Pathways in Colorectal Cancer. Clinical Cancer Research, 2021, 27, 3234-3242.	7.0	24
17	Clinical and Functional Characterization of Atypical KRAS/NRAS Mutations in Metastatic Colorectal Cancer. Clinical Cancer Research, 2021, 27, 4587-4598.	7.0	14
18	Large-scale analysis of KMT2 mutations defines a distinctive molecular subset with treatment implication in gastric cancer. Oncogene, 2021, 40, 4894-4905.	5.9	19

#	Article	IF	Citations
19	Metastatic colorectal cancer: Advances in the folate-fluoropyrimidine chemotherapy backbone. Cancer Treatment Reviews, 2021, 98, 102218.	7.7	33
20	Global mapping of cancers: The Cancer Genome Atlas and beyond. Molecular Oncology, 2021, 15, 2823-2840.	4.6	55
21	Lessons Learned in Managing Patients with Colorectal Cancer During the COVID-19 Pandemic. Current Treatment Options in Oncology, 2021, 22, 93.	3.0	5
22	Evaluating the impact of age on immune checkpoint therapy biomarkers. Cell Reports, 2021, 36, 109599.	6.4	27
23	Molecular characterization of squamous cell carcinoma of the anal canal. Journal of Gastrointestinal Oncology, 2021, 12, 2423-2437.	1.4	7
24	Molecular differences between lymph nodes and distant metastases compared with primaries in colorectal cancer patients. Npj Precision Oncology, 2021, 5, 95.	5.4	9
25	Excitement for our future. Oncotarget, 2021, 12, 2307-2307.	1.8	0
26	Cases in the management of metastatic colorectal cancer: use of regorafenib as a bridge to chemotherapy. Clinical Advances in Hematology and Oncology, 2021, 19 Suppl 6, 1-8.	0.3	0
27	Neuroendocrine tumor causing ureteral obstruction in a patient with prior ileal conduit.. Canadian Journal of Urology, 2021, 28, 10953-10955.	0.0	0
28	Considerations in the management of younger patients with colorectal cancer.. Clinical Advances in Hematology and Oncology, 2021, 19 Suppl 16, 1-20.	0.3	0
29	Addressing the needs of younger patients with colorectal cancer.. Clinical Advances in Hematology and Oncology, 2021, 19 Suppl 16, 9-11.	0.3	0
30	Considerations in the management of younger patients With colorectal cancer: Q&A.. Clinical Advances in Hematology and Oncology, 2021, 19 Suppl 16, 15-17.	0.3	0
31	Workup and Management of Immune-Mediated Colitis in Patients Treated with Immune Checkpoint Inhibitors. Oncologist, 2020, 25, 197-202.	3.7	12
32	The impact of ARID1A mutation on molecular characteristics in colorectal cancer. European Journal of Cancer, 2020, 140, 119-129.	2.8	37
33	Cancer predictive studies. Biology Direct, 2020, 15, 18.	4.6	37
34	Molecular Characterization of Appendiceal Goblet Cell Carcinoid. Molecular Cancer Therapeutics, 2020, 19, 2634-2640.	4.1	14
35	A Phase I/II Study of Veliparib (ABT-888) in Combination with 5-Fluorouracil and Oxaliplatin in Patients with Metastatic Pancreatic Cancer. Clinical Cancer Research, 2020, 26, 5092-5101.	7.0	28
36	A Phase I Study of Ribociclib Plus Everolimus in Patients with Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy. Journal of Pancreatic Cancer, 2020, 6, 45-54.	0.9	15

#	Article	IF	Citations
37	Comprehensive Genomic Profiling of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs). Clinical Cancer Research, 2020, 26, 5943-5951.	7.0	55
38	Liquid biopsies and cancer omics. Cell Death Discovery, 2020, 6, 131.	4.7	52
39	Colorectal cancer care in the age of coronavirus: strategies to reduce risk and maintain benefit. Colorectal Cancer, 2020, 9, .	0.8	12
40	WRN-Mutated Colorectal Cancer Is Characterized by a Distinct Genetic Phenotype. Cancers, 2020, 12, 1319.	3.7	10
41	Medical Oncologistsâ€™ Perspectives on How the Results of the IDEA Collaboration Impact the Adjuvant Treatment of Stage III Colon Cancer. Oncologist, 2020, 25, 229-234.	3.7	9
42	Comprehensive tumor profiling reveals unique molecular differences between peritoneal metastases and primary colorectal adenocarcinoma. Journal of Surgical Oncology, 2020, 121, 1320-1328.	1.7	16
43	Molecular profile of BRCA-mutated biliary tract cancers. ESMO Open, 2020, 5, e000682.	4.5	64
44	Relationship between <scp>MLH1</scp>, <scp>PMS2</scp>, <scp>MSH2</scp> and <scp>MSH6</scp> geneâ€specific alterations and tumor mutational burden in 1057 microsatellite instabilityâ€high solid tumors. International Journal of Cancer, 2020, 147, 2948-2956.	5.1	102
45	How to incorporate a chemo-free interval into the management of metastatic colorectal cancer. Clinical Advances in Hematology and Oncology, 2020, 18 Suppl 16, 1-24.	0.3	0
46	Third-line treatments for the management of metastatic colorectal cancer: why to change the mechanism of action after frontline chemotherapy, and insights into management during the COVID-19 pandemic. Clinical Advances in Hematology and Oncology, 2020, 18 Suppl 16, 6-14.	0.3	0
47	How to incorporate a chemo-free interval into the management of metastatic colorectal cancer: discussion. Clinical Advances in Hematology and Oncology, 2020, 18 Suppl 16, 20-21.	0.3	0
48	Impact of Patient Age on Molecular Alterations of Left-Sided Colorectal Tumors. Oncologist, 2019, 24, 319-326.	3.7	29
49	Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets. Journal of Gastrointestinal Oncology, 2019, 10, 652-662.	1.4	106
50	Colon Cancer in Young Adults: Trends and Their Implications. Current Oncology Reports, 2019, 21, 3.	4.0	74
51	Molecular Profiling of Appendiceal Adenocarcinoma and Comparison with Right-sided and Left-sided Colorectal Cancer. Clinical Cancer Research, 2019, 25, 3096-3103.	7.0	65
52	The current state of molecular testing in the treatment of patients with solid tumors, 2019. Ca-A Cancer Journal for Clinicians, 2019, 69, 305-343.	329.8	203
53	Gene-specific features (MLH1, MSH2, MSH6, PMS2) of mismatch repair (MMR) protein expression and somatic mutations (muts), microsatellite instability (MSI) and tumor mutational burden (TMB) in MSI-H and MMR-mutated tumor genomic profiles (TGPs).. Journal of Clinical Oncology, 2019, 37, 505-505.	1.6	1
54	Association of DNA damage response and repair genes (DDR) mutations and microsatellite instability (MSI), PD-L1 expression, tumor mutational burden (TMB) in gastroesophageal cancers.. Journal of Clinical Oncology, 2019, 37, 60-60.	1.6	5

#	Article	IF	Citations
55	Characteristics of colorectal cancer (CRC) patients with BRCA1 and BRCA2 mutations.. Journal of Clinical Oncology, 2019, 37, 606-606.	1.6	5
56	Comprehensive molecular profiling of signet-ring-cell carcinoma (SRCC) from the stomach and colon.. Journal of Clinical Oncology, 2019, 37, 63-63.	1.6	0
57	Biomarkers for immune therapy in gastrointestinal cancers. Clinical Advances in Hematology and Oncology, 2019, 17, 109-119.	0.3	4
58	Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers. Molecular Cancer Research, 2018, 16, 805-812.	3.4	169
59	A phase 2 study of the PARP inhibitor veliparib plus temozolomide in patients with heavily pretreated metastatic colorectal cancer. Cancer, 2018, 124, 2337-2346.	4.1	47
60	Poly-ligand profiling differentiates trastuzumab-treated breast cancer patients according to their outcomes. Nature Communications, 2018, 9, 1219.	12.8	20
61	A phase I study of intravenous artesunate in patients with advanced solid tumor malignancies. Cancer Chemotherapy and Pharmacology, 2018, 81, 587-596.	2.3	66
62	Microsatellite instability status determined by nextâ€generation sequencing and compared with <scp>PD</scp>â€L1 and tumor mutational burden in 11,348 patients. Cancer Medicine, 2018, 7, 746-756.	2.8	348
63	Five-Fraction Stereotactic Body Radiation Therapy (SBRT) and Chemotherapy for the Local Management of Metastatic Pancreatic Cancer. Journal of Gastrointestinal Cancer, 2018, 49, 116-123.	1.3	22
64	Prevalence of Homologous Recombinationâ€“Related Gene Mutations Across Multiple Cancer Types. JCO Precision Oncology, 2018, 2018, 1-13.	3.0	215
65	Reprint of: Circulating cell-free DNA mutation patterns in early and late stage colon and pancreatic cancer. Cancer Genetics, 2018, 228-229, 131-142.	0.4	5
66	Underuse of exon mutational analysis for gastrointestinal stromal tumors. Journal of Surgical Research, 2018, 231, 43-48.	1.6	4
67	Molecular Variances Between Right- and Left-sided Colon Cancers. Current Colorectal Cancer Reports, 2018, 14, 152-158.	0.5	5
68	Comparative Molecular Analyses of Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, and Gastric Adenocarcinoma. Oncologist, 2018, 23, 1319-1327.	3.7	131
69	Circadian clock gene PER1 mutations in colorectal cancer (CRC).. Journal of Clinical Oncology, 2018, 36, 12106-12106.	1.6	2
70	Impact of MLH1, PMS2, MSH2, and MSH6 alterations on tumor mutation burden (TMB) and PD-L1 expression in 1,057 microsatellite instability-high (MSI-H) tumors.. Journal of Clinical Oncology, 2018, 36, 3572-3572.	1.6	6
71	Safety and clinical activity of durvalumab monotherapy in patients with gastroesophageal cancers.. Journal of Clinical Oncology, 2018, 36, 4032-4032.	1.6	4
72	Comprehensive molecular profiling of paired patient samples of primary and metastatic (met) pancreatic ductal adenocarcinoma (PDAC).. Journal of Clinical Oncology, 2018, 36, 4114-4114.	1.6	2

#	Article	IF	Citations
73	A phase I/II study of ribociclib plus everolimus in patients (pts) with metastatic pancreatic adenocarcinoma (mPAC) refractory to chemotherapy.. Journal of Clinical Oncology, 2018, 36, TPS4150-TPS4150.	1.6	2
74	Neutrophil-to-lymphocyte ratio as a prognostic marker for metastatic pancreatic cancer.. Journal of Clinical Oncology, 2018, 36, 251-251.	1.6	1
75	Molecular characterization of intestinal (IS) and diffuse subtypes (DS) of gastric adenocarcinomas.. Journal of Clinical Oncology, 2018, 36, 60-60.	1.6	0
76	Molecular profiling to predict outcomes following Y90 radioembolization for metastatic colorectal cancer.. Journal of Clinical Oncology, 2018, 36, 686-686.	1.6	0
77	Comparative effectiveness of nab-paclitaxel plus gemcitabine versus FOLFIRINOX in metastatic pancreatic cancer: A nationwide chart review in the United States.. Journal of Clinical Oncology, 2018, 36, 376-376.	1.6	6
78	Does stereotactic body radiation therapy have a role in oligoprogressive metastatic colorectal cancer?. Journal of Clinical Oncology, 2018, 36, 755-755.	1.6	0
79	Differences in molecular profiles of males and females with colorectal cancer (CRC).. Journal of Clinical Oncology, 2018, 36, 623-623.	1.6	0
80	Evaluation of outcomes over time (1998-2009) of patients (pts) with stage III colon cancer receiving adjuvant FOLFOX: Analysis of 7,230 patients from MOSAIC, C07, C08, N0147, AVANT, and PETACC8 trials in the ACCENT Database.. Journal of Clinical Oncology, 2018, 36, 724-724.	1.6	0
81	Outcomes over time (1998-2009) of stage II colon cancer patients (pts) receiving adjuvant FOLFOX: Pooled analysis of 1,122 pts in the ACCENT database.. Journal of Clinical Oncology, 2018, 36, 728-728.	1.6	14
82	Association of increased T cell infiltrates in the invasive margin with relapse-free survival in patients with cholangiocarcinoma (CCA).. Journal of Clinical Oncology, 2018, 36, e15001-e15001.	1.6	0
83	Molecular analyses of left- and right-sided tumors in adolescents and young adults (AYA) with colorectal cancer (CRC).. Journal of Clinical Oncology, 2018, 36, 3577-3577.	1.6	0
84	Molecular characterization of appendiceal cancer and comparison with right-sided (R-CRC) and left-sided colorectal cancer (L-CRC).. Journal of Clinical Oncology, 2018, 36, 3611-3611.	1.6	0
85	Comprehensive genomic profiling of 724 gastroenteropancreatic neuroendocrine tumors (GEP-NETs).. Journal of Clinical Oncology, 2018, 36, 4098-4098.	1.6	0
86	Comprehensive tumor genomic testing in the community oncology setting in the United States.. Journal of Clinical Oncology, 2018, 36, e24304-e24304.	1.6	0
87	Profiling for microsatellite instability (MSI) and mismatch repair (MMR) among patients with colon cancer in real world settings.. Journal of Clinical Oncology, 2018, 36, e15622-e15622.	1.6	0
88	Circulating cell-free DNA mutation patterns in early and late stage colon and pancreatic cancer. Cancer Genetics, 2017, 218-219, 39-50.	0.4	42
89	Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers. Oncotarget, 2017, 8, 86356-86368.	1.8	147
90	Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2017, 35, 3338-3346.	1.6	69

#	Article	IF	Citations
91	Safety of selective internal radiation therapy (SIRT) with yttrium-90 microspheres combined with systemic anticancer agents: expert consensus. Journal of Gastrointestinal Oncology, 2017, 8, 1079-1099.	1.4	34
92	Characterization of tumor mutation load (TML) in solid tumors.. Journal of Clinical Oncology, 2017, 35, 11517-11517.	1.6	19
93	Impact of patient age on molecular alterations in left-sided colorectal tumors.. Journal of Clinical Oncology, 2017, 35, 3592-3592.	1.6	4
94	Safety and clinical activity of durvalumab monotherapy in patients with hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2017, 35, 4071-4071.	1.6	107
95	Quantification and expert evaluation of evidence for chemopredictive biomarkers to personalize cancer treatment. Oncotarget, 2017, 8, 37923-37934.	1.8	23
96	Molecular characteristics of hepatocellular carcinomas from different age groups. Oncotarget, 2017, 8, 101591-101598.	1.8	4
97	Colorectal cancer: Impact of primary tumor location on genetic alterations.. Journal of Clinical Oncology, 2017, 35, 3578-3578.	1.6	1
98	Phase 1 Study of CEP-37250/KHK2804, a Tumor-specific Anti-glycoconjugate Monoclonal Antibody, in Patients with Advanced Solid Tumors. Targeted Oncology, 2016, 11, 807-814.	3.6	4
99	Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma. Molecular Therapy, 2016, 24, 1150-1158.	8.2	114
100	Circulating microRNA profile predicts disease progression in patients receiving second-line treatment of lapatinib and capecitabine for metastatic pancreatic cancer. Oncology Letters, 2016, 11, 1645-1650.	1.8	20
101	Patient preference and decision-making for initiating metastatic colorectal cancer medical treatment. Journal of Cancer Research and Clinical Oncology, 2016, 142, 699-706.	2.5	16
102	Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair. Journal of the National Cancer Institute, 2016, 108, djv437.	6.3	20
103	Intratumoral CD3 and CD8 T-cell Densities Associated with Relapse-Free Survival in HCC. Cancer Immunology Research, 2016, 4, 419-430.	3.4	247
104	Challenges That Hinder the Translation of Clinical Advances Into Practice: Results From an International Assessment in Colorectal Cancer. Clinical Colorectal Cancer, 2016, 15, 54-66.	2.3	7
105	A paradigm shift from one-size-fits-all to tailor-made therapy for metastatic colorectal cancer. Clinical Advances in Hematology and Oncology, 2016, 14, 116-28.	0.3	7
106	Approach to the medical management of surgically resectable gastric cancer. Clinical Advances in Hematology and Oncology, 2016, 14, 129-35.	0.3	0
107	Trifluridine/tipiracil and regorafenib: new weapons in the war against metastatic colorectal cancer. Clinical Advances in Hematology and Oncology, 2016, 14, 630-8.	0.3	6
108	Results of an abbreviated phase-II study with the Akt Inhibitor MK-2206 in Patients with Advanced Biliary Cancer. Scientific Reports, 2015, 5, 12122.	3.3	58

#	Article	IF	Citations
109	Phase II study of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma. Cancer Chemotherapy and Pharmacology, 2015, 76, 1073-1079.	2.3	31
110	Phase II study of lapatinib and capecitabine in second-line treatment for metastatic pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2015, 76, 1309-1314.	2.3	44
111	Rechallenging 5-Fluorouracil in a Patient With Capecitabine-Induced Ventricular Fibrillation. Clinical Colorectal Cancer, 2015, 14, 198-201.	2.3	6
112	Irreversible Multitargeted ErbB Family Inhibitors for Therapy of Lung and Breast Cancer. Current Cancer Drug Targets, 2015, 14, 775-793.	1.6	33
113	A Phase 1 Study of 131I-CLR1404 in Patients with Relapsed or Refractory Advanced Solid Tumors: Dosimetry, Biodistribution, Pharmacokinetics, and Safety. PLoS ONE, 2014, 9, e111652.	2.5	25
114	Losing Sight of Our Primary Target: Curing Cancer. Seminars in Oncology, 2014, 41, 143-144.	2.2	0
115	Utilization of bevacizumab in US elderly patients with colorectal cancer receiving chemotherapy. Journal of Oncology Pharmacy Practice, 2014, 20, 332-340.	0.9	12
116	Conference Scene: Fighting a smarter war against cancer. Colorectal Cancer, 2014, 3, 131-133.	0.8	1
117	Maintenance therapy in metastatic colorectal cancer. Clinical Advances in Hematology and Oncology, 2014, 12, 388-90.	0.3	0
118	A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors. Investigational New Drugs, 2013, 31, 399-408.	2.6	41
119	Phase I dose-escalation study of afatinib, an ErbB family blocker, plus docetaxel in patients with advanced cancer. Future Oncology, 2013, 9, 271-281.	2.4	16
120	Microsatellite instability in colorectal cancer. Clinical Advances in Hematology and Oncology, 2013, 11, 659-61.	0.3	2
121	Implementation of a Performance Improvement Initiative in Colorectal Cancer Care. Journal of Oncology Practice, 2012, 8, 309-314.	2.5	12
122	The PARSC trial, a prospective study for the assessment of recurrence risk in stage II colon cancer (CC) patients using ColoPrint.. Journal of Clinical Oncology, 2012, 30, 678-678.	1.6	5
123	Philanthropy, Advocacy and Colon Cancer. Clinical Colorectal Cancer, 2011, 10, 290.	2.3	1
124	Molecularly Targeted Therapy for Metastatic Colon Cancer: Proven Treatments and Promising New Agents. Current Colorectal Cancer Reports, 2010, 6, 193-198.	0.5	2
125	Safety of capecitabine: a review. Expert Opinion on Drug Safety, 2010, 9, 831-841.	2.4	73
126	Risk assessment in Stage II colorectal cancer. Oncology, 2010, 24, 9-13.	0.5	26

#	Article	IF	Citations
127	Fighting a smarter war on cancer. Oncology, 2010, 24, 193-4.	0.5	0
128	ISGIO and the Future of GI Oncology: A Very Different Society Making a Very Important Difference. Gastrointestinal Cancer Research: GCR, 2009, 3, 1-2.	0.7	0
129	Too much information. Gastrointestinal Cancer Research: GCR, 2009, 3, 43-4.	0.7	0
130	Heading in the right direction. Gastrointestinal Cancer Research: GCR, 2009, 3, 89.	0.7	0
131	ISGIO: Setting the Standard of Care for the Future. Gastrointestinal Cancer Research: GCR, 2009, 3, 133.	0.7	0
132	Accomplishments in 2008 in the adjuvant treatment of colon cancer. Gastrointestinal Cancer Research: GCR, 2009, 3, S2-7.	0.7	1
133	Integrating Targeted Agents into Therapeutic Regimens for Patients with Resectable Colorectal Cancer. Clinical Colorectal Cancer, 2008, 7, S63-S66.	2.3	0
134	Carcinoembryonic antigen as a vaccine target. Expert Review of Vaccines, 2008, 7, 987-993.	4.4	12
135	Health care reform: will we pass the external review?. Gastrointestinal Cancer Research: GCR, 2008, 2, 53.	0.7	0
136	Managing potentially resectable metastatic colon cancer. Gastrointestinal Cancer Research: GCR, 2008, 2, S23-6.	0.7	8
137	More fanfare for metastatic colon cancer resections. Gastrointestinal Cancer Research: GCR, 2007, 1, 28.	0.7	2
138	Adjuvant Therapy for Stage II and III Colon Cancer: Consensus Report of the International Society of Gastrointestinal Oncology. Gastrointestinal Cancer Research: GCR, 2007, 1, 146-54.	0.7	26
139	Bevacizumab in the treatment of colorectal cancer. Clinical Advances in Hematology and Oncology, 2007, 5, 8-9.	0.3	6
140	The development of novel agents for the treatment of colorectal cancer: a critical review of current practice and some suggestions for the future. Clinical Advances in Hematology and Oncology, 2007, 5, 167-72.	0.3	3
141	Clinical experiences with G17DT in gastrointestinal malignancies. Expert Review of Anticancer Therapy, 2006, 6, 487-492.	2.4	4
142	Optimum Use of Biologics and Role of Maintenance Therapy in Colon Cancer. Seminars in Oncology, 2006, 33, 33-35.	2.2	16
143	Clinical implications of the mechanism of epidermal growth factor receptor inhibitors. Cancer, 2006, 107, 1207-1218.	4.1	165
144	The Role of Bevacizumab as First-line Therapy for Colon Cancer. Seminars in Oncology, 2005, 32, 43-47.	2.2	42

#	Article	IF	Citations
145	Phase I Study of Sequential Vaccinations With Fowlpox-CEA(6D)-TRICOM Alone and Sequentially With Vaccinia-CEA(6D)-TRICOM, With and Without Granulocyte-Macrophage Colony-Stimulating Factor, in Patients With Carcinoembryonic Antigenâ€“Expressing Carcinomas. Journal of Clinical Oncology, 2005, 23, 720-731.	1.6	290
146	Novel vaccines for the treatment of gastrointestinal cancers. Oncology, 2005, 19, 1557-65; discussion 1566, 1568 passim.	0.5	1
147	The impact of targeted therapy on the treatment of colorectal cancer. Oncology, 2005, 19, 19-24.	0.5	2
148	A Phase II Trial of ISIS 3521 in Patients with Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2004, 4, 268-274.	2.3	34
149	TRICOM: enhanced vaccines as anticancer therapy. Expert Review of Vaccines, 2004, 3, 397-402.	4.4	17
150	Thrombotic Thrombocytopenic Purpura as a Marker for Disease Progression in a Patient with Metastatic Rectal Cancer.. Blood, 2004, 104, 4032-4032.	1.4	0
151	Carcinoembryonic antigen-based vaccines. Seminars in Oncology, 2003, 30, 30-36.	2.2	60
152	Superiority of Oxaliplatin and Fluorouracil-Leucovorin Compared With Either Therapy Alone in Patients With Progressive Colorectal Cancer After Irinotecan and Fluorouracil-Leucovorin: Interim Results of a Phase III Trial. Journal of Clinical Oncology, 2003, 21, 2059-2069.	1.6	613
153	Phase I Study of Prolonged Infusion Bryostatin-1 in Patients. Cancer Biology and Therapy, 2002, 1, 409-416.	3.4	27
154	Phase I trial of irinotecan and epirubicin in advanced cancer. Preliminary report. Oncology, 2002, 16, 17-9.	0.5	0
155	The use of a rapid ELISPOT assay to analyze peptide-specific immune responses in carcinoma patients to peptide vs. recombinant poxvirus vaccines. Cancer Immunology, Immunotherapy, 2000, 49, 517-529.	4.2	73
156	Genetic testing for colon cancer susceptibility: Anticipated reactions of patients and challenges to providers. , 1996, 69, 58-61.		92
157	Phase I trial of a novel matrix metalloproteinase inhibitor batimastat (BB-94) in patients with advanced cancer. Investigational New Drugs, 1996, 14, 193-202.	2.6	105
158	The clinical experience with antiangiogenic agents. Breast Cancer Research and Treatment, 1995, 36, 253-261.	2.5	11
159	Stability of cisplatin and ondansetron hydrochloride in admixtures for continuous infusion. American Journal of Health-System Pharmacy, 1995, 52, 2570-2573.	1.0	2
160	Clinical Pharmacokinetics and Pharmacology of Trimetrexate. Clinical Pharmacokinetics, 1994, 26, 190-200.	3.5	21